These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

65 related items for PubMed ID: 20430173

  • 1. Kidney transplantation achievements in Mongolia.
    Jambaljav L, Nyamsuren D, Byambadash B, Ganbold L.
    Transplant Proc; 2010 Apr; 42(3):791-2. PubMed ID: 20430173
    [Abstract] [Full Text] [Related]

  • 2. Steroid-free tacrolimus monotherapy after pretransplantation thymoglobulin or Campath and laparoscopy in living donor renal transplantation.
    Tan HP, Kaczorowski D, Basu A, McCauley J, Marcos A, Donaldson J, Unruh M, Randhawa P, Zeevi A, Shapiro R.
    Transplant Proc; 2005 Dec; 37(10):4235-40. PubMed ID: 16387087
    [Abstract] [Full Text] [Related]

  • 3. Experience with Alemtuzumab (Campath-1H) as induction agent in renal transplantation followed by steroid-free immunosuppression.
    Baez Y, Giron F, Niño-Murcia A, Rodríguez J, Salcedo S.
    Transplant Proc; 2008 Apr; 40(3):697-9. PubMed ID: 18454990
    [Abstract] [Full Text] [Related]

  • 4. Pediatric living donor kidney transplantation under alemtuzumab pretreatment and tacrolimus monotherapy: 4-year experience.
    Tan HP, Donaldson J, Ellis D, Moritz ML, Basu A, Morgan C, Vats AN, Erkan E, Shapiro R.
    Transplantation; 2008 Dec 27; 86(12):1725-31. PubMed ID: 19104412
    [Abstract] [Full Text] [Related]

  • 5. Campath-1H (alemtuzumab) as an induction agent for the prevention of graft rejection and preservation of renal function in kidney transplant patients: Philippine 3-year follow-up.
    Muñoz AS, Cabanayan-Casasola CB, Danguilan RA, Padua FB, Ona ET.
    Transplant Proc; 2008 Sep 27; 40(7):2230-3. PubMed ID: 18790200
    [Abstract] [Full Text] [Related]

  • 6. Reversal of acute cellular rejection after renal transplantation with Campath-1H.
    Basu A, Ramkumar M, Tan HP, Khan A, McCauley J, Marcos A, Fung JJ, Starzl TE, Shapiro R.
    Transplant Proc; 2005 Mar 27; 37(2):923-6. PubMed ID: 15848576
    [Abstract] [Full Text] [Related]

  • 7. Alemtuzumab versus interleukin-2 receptor antibodies induction in living donor kidney transplantation.
    Sampaio MS, Kadiyala A, Gill J, Bunnapradist S.
    Transplantation; 2009 Oct 15; 88(7):904-10. PubMed ID: 19935462
    [Abstract] [Full Text] [Related]

  • 8. Preliminary experience with alemtuzumab induction therapy combined with maintenance low-dose tacrolimus monotherapy in small-bowel transplantation in China.
    Yuan-Xin L, Ning L, You-Sheng L, Xiao-Dong N, Ming L, Jian W, Jie-Shou L.
    Transplant Proc; 2010 Oct 15; 42(1):29-34. PubMed ID: 20172275
    [Abstract] [Full Text] [Related]

  • 9. Alemtuzumab induction with tacrolimus monotherapy in de novo renal transplantation.
    Villanueva ME, Muñoz AS, Casasola CC, Africa JB, Danguilan RA, Ona ET.
    Transplant Proc; 2008 Sep 15; 40(7):2222-5. PubMed ID: 18790198
    [Abstract] [Full Text] [Related]

  • 10. Campath induction for kidney transplantation: report of 297 cases.
    Ortiz J, Palma-Vargas J, Wright F, Bingaman A, Agha I, Rosenblatt S, Foster P.
    Transplantation; 2008 Jun 15; 85(11):1550-6. PubMed ID: 18551058
    [Abstract] [Full Text] [Related]

  • 11. Living-related donor renal transplantation in HIV+ recipients using alemtuzumab preconditioning and steroid-free tacrolimus monotherapy: a single center preliminary experience.
    Tan HP, Kaczorowski DJ, Basu A, Khan A, McCauley J, Marcos A, Fung JJ, Starzl TE, Shapiro R.
    Transplantation; 2004 Dec 15; 78(11):1683-8. PubMed ID: 15591960
    [Abstract] [Full Text] [Related]

  • 12. Alemtuzumab induction in deceased donor kidney transplantation.
    Shin M, Song SH, Kim JM, Kwon CH, Joh JW, Lee SK, Kim SJ.
    Transplant Proc; 2011 Dec 15; 43(6):2365-78. PubMed ID: 21839271
    [Abstract] [Full Text] [Related]

  • 13. Alemtuzumab induction therapy in highly sensitized kidney transplant recipients.
    Lü TM, Yang SL, Wu WZ, Tan JM.
    Chin Med J (Engl); 2011 Mar 15; 124(5):664-8. PubMed ID: 21518554
    [Abstract] [Full Text] [Related]

  • 14. Pilot study of rapid steroid elimination with alemtuzumab induction therapy in kidney and pancreas transplantation.
    Sundberg AK, Roskopf JA, Hartmann EL, Farney AC, Rohr MS, Stratta RJ.
    Transplant Proc; 2005 Mar 15; 37(2):1294-6. PubMed ID: 15848701
    [Abstract] [Full Text] [Related]

  • 15. Kidney transplantation in Mongolia using effective and economical immunosuppression - a three-year experience.
    Tumurbaatar B, Nyamsuren D, Byambadorj B, Bayan-Undur D, Jambaljav L, Byambadash B, Sarantsetseg J, Ganbold L.
    Ann Transplant; 2012 Mar 15; 17(1):132-9. PubMed ID: 22466920
    [Abstract] [Full Text] [Related]

  • 16.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 17. Annual trends and triple therapy--1991-2000.
    Nishikawa K, Terasaki PI.
    Clin Transpl; 2001 Mar 15; ():247-69. PubMed ID: 12211788
    [Abstract] [Full Text] [Related]

  • 18. The use of Campath-1H as induction therapy in renal transplantation: preliminary results.
    Ciancio G, Burke GW, Gaynor JJ, Mattiazzi A, Roohipour R, Carreno MR, Roth D, Ruiz P, Kupin W, Rosen A, Esquenazi V, Tzakis AG, Miller J.
    Transplantation; 2004 Aug 15; 78(3):426-33. PubMed ID: 15316372
    [Abstract] [Full Text] [Related]

  • 19.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 20. Current advantage of FK 506 in cadaveric kidney transplantation.
    Ciancio G, Rosen A, Loreto-Grand B, Burke G, Siquijor A, Luque C, Esquenazi V, Miller J.
    Transplant Proc; 1996 Apr 15; 28(2):1000-1. PubMed ID: 8623207
    [No Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 4.